1. CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR YOUNG PATIENTS WITH FIRST‐LINE FOLLICULAR LYMPHOMA: A POOLED ANALYSIS OF 4249 PATIENTS FROM THE FLASH DATABASE. (June 2017) Authors: Fornecker, L.; Ou, F.; Dixon, J.G.; Casulo, C.; Hoster, E.; Hiddemann, W.; Sebban, C.; Morschhauser, F.; Marcus, R.; Hochster, H.; Rummel, M.; Hagenbeeck, A.; Kimby, E.; Herold, M.; Peterson, B.A.; Gyan, E.; Ladetto, M.; Zucca, E.; Nielsen, T.; Foon, K. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST‐AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12‐YEAR FOLLOW‐UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL. (June 2017) Authors: Pettengell, R.; Uddin, R.; Boumendil, A.; Robinson, S.P.; Smith, G.; Hawkins, T.; Metzner, B.; Caballero, M.D.; Tilly, H.; Romejko‐Jarosinska, J.; Bence‐Bruckler, I.; To, B.; Niemann, C.; Kimby, E.; Dreger, P.; Schmitz, N.; Goldstone, A.H.; Montoto, S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Erratum to "Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS)" [Leukemia Res. 13(1) (1989) 31–37]. (June 2017) Authors: Garcia, C.; Rosén, A.; Kimby, E.; Aguilar-Santelises, M.; Jondal, M.; Björkhilm, M.; Holm, G.; Mellstedt, H. Journal: Leukemia research Issue: Volume 57(2017:Jun.) Page Start: 127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY‐FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK). (12th June 2019) Authors: Moccia, A.; Schär, S.; Hayoz, S.; Pirosa, M.; Taverna, C.; Novak, U.; Kimby, E.; Ghielmini, M.; Zucca, E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY. A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL. (12th June 2019) Authors: Menter, T.; Tzankov, A.; Zucca, E.; Kimby, E.; Vanazzi, A.; Østenstad, B.; Mey, U.J.; Rauch, D.; Wahlin, B.; Hitz, F.; Hernberg, M.; Johansson, A.; de Nully Brown, P.; Hagberg, H.; Hawle, H.; Hayoz, S.; Dirnhofer, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Searching the haematology and inflammation archives of Journal of Internal Medicine. (December 2013) Authors: Palmblad, J.; Kimby, E. Journal: Journal of internal medicine Issue: Volume 274:Number 6(2013:Dec.) Page Start: 541 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Targeting of B‐cell receptor signalling in B‐cell malignancies. (14th March 2017) Authors: Jerkeman, M.; Hallek, M.; Dreyling, M.; Thieblemont, C.; Kimby, E.; Staudt, L. Journal: Journal of internal medicine Issue: Volume 282:Number 5(2017) Page Start: 415 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Targets for Ibrutinib Beyond B Cell Malignancies. (September 2015) Authors: Berglöf, A.; Hamasy, A.; Meinke, S.; Palma, M.; Krstic, A.; Månsson, R.; Kimby, E.; Österborg, A.; Smith, C. I. E. Journal: Scandinavian journal of immunology Issue: Volume 82:Number 3(2015:Sep.) Page Start: 208 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA "TRANSFORMED" BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE. (June 2017) Authors: Federico, M.; Caballero, D.; Marcheselli, L.; Tarantino, V.; Sarkozy, C.; Lopez Guillermo, A.; Wondergem, M.; Kimby, E.; Rusconi, C.; Zucca, E.; Montoto, S.; da Silva, M.G.; Aurer, I.; Paszkiewicz‐Kozik, E.; Cartron, G.; Morschhauser, F.; Alcoceba, M.; Chamuleau, M.; Lockmer, S.; Minoia, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗